At its meeting on 18 July 2022 the Transparency Council adopted Opinion No. 115/2022 on the active substance prednisone for the following off-label indications: obstructive pulmonary diseases – in cases other than those specified in the SmPC; autoimmune diseases – in cases other than those specified in the SmPC; conditions after organ, limb, tissue, cell or marrow transplantation.
Publication in Public Information Bulletin (BIP)